We're actually doing a study right now, as I mentioned, with Deloitte. We've just started looking at Canada's competitiveness. It's to try to assess where we are in relation to some of the major trading partners. Our study looks at Canada in relation to the United States, in relation to the U.K. and in relation to Australia, specifically looking at the regulatory burden and the return on investment for companies investing in Canada. While we may have the same types of regulations as we do in other countries, the return on investment is very different depending on which country you're in and where some of the incentives are.
On some of the trade agreements, as we were inputting into them, we were looking for similar incentives as they had in other countries. For instance, in the United States they have three years of data protection for consumer health products—not the prescription side, but the consumer health products. We were looking for something similar so our companies here could benefit from that, but in those trade agreements Canada had the option to opt out of that sort of protection. It's the same with the EU where there's a year of protection; but Canada doesn't have that. If we're looking at how these trade agreements can help, we're seeing that our position was really trying to get the same benefits for Canadian companies as the companies have in other countries so we can work on an even playing field.